Chief Scientific Officer
Professor Jones is Chair in Pharmaceutical Medicine at the Institute of Pharmaceutical Science, King’s College London, and brings deep R&D expertise spanning academia and industry. He began his career at Pfizer in Sandwich, Kent, before completing a PhD at King’s College London. He subsequently served as Head of Research and Development at MedPharm Ltd, where he led the in-house technology development, before returning to academia to focus on pharmaceutical innovation.
Professor Jones leads the Pharmaceutical Dermatology Group at King’s, a research team dedicated to designing advanced pharmaceutical formulations and medical devices that overcome the skin barrier for both molecule delivery and biomarker extraction. His work underpins several cutting-edge technologies, including those being commercialised by Epinostics. He also directs the Centre for Pharmaceutical Development Research, which operates with an annual turnover of £8 million and a strong track record of industry collaboration. His research has attracted over £4 million in competitive grant funding, resulting in more than 100 peer-reviewed publications and leading to 11 granted patents. He has successfully supervised over 40 PhD students and continues to serve as a valued consultant to the pharmaceutical industry and an expert witness in intellectual property litigation.
Chief Technology Officer
Our Team
Clinical Director
Dr. Mohamed A. Alhnan is a Reader in Pharmaceutical Medicine at King’s College London and a leading innovator at the intersection of pharmaceutical science, material engineering, and digital manufacturing. Since joining King’s in 2018, he has advanced a research portfolio that pioneers the use of 3D printing and smart manufacturing technologies to transform drug delivery and formulation design. A registered UK pharmacist since 2011, Dr. Alhnan completed his PhD at the London School of Pharmacy (now UCL School of Pharmacy), focusing on site-specific oral drug delivery. His early career included industry collaborations and academic posts at the University of Central Lancashire, where he was appointed Senior Lecturer.
Dr. Alhnan’s research is driving the digitalisation and personalisation of medicine. He applies cutting-edge advances in materials science and electronics to develop next-generation dosage forms that are responsive to biosensors, environmental changes, and individual patient needs. His work spans 3D printed pharmaceuticals, oral delivery of biologics, nanomedicine manufacturing, and smart coating technologies.
His work has achieved multiple scientific and technological firsts, including the use of pharmaceutical-grade polymers in fused deposition modelling (FDM) 3D printing, the creation of the first 3D-printed tablets meeting US and British Pharmacopoeial standards for delayed-release formulations, and the development of the first 3D-printed liquid capsules. He also patented an innovative tablet architecture designed for rapid disintegration and improved dissolution, advancing the performance of oral delivery systems. Dr. Alhnan actively collaborates with industry and clinical partners to commercialise 3D-printed dosage forms and is working with two global pharmaceutical manufacturers to scale up next-generation coating technologies for nutraceutical products.
Dr. Karl Lawrence is a Research Fellow at the Institute of Pharmaceutical Science, King’s College London, specialising in non-invasive diagnostics and dermatological device innovation.
His work has focused on the development and clinical validation of Epinostics’ patented biomarker extraction device, managing several clinical validation studies. Dr. Lawrence completed his BASF-funded PhD at King’s College London within St. John’s Institute of Dermatology, where he investigated the effects of UV and visible light on the skin and developed novel photoprotection strategies. alisation, and public engagement.
Following his PhD, Dr. Lawrence held a postdoctoral position at Queen Mary University of London in the Cell Biology and Cutaneous Research department, where he contributed to the development and biological validation of a next-generation ex vivo skin tissue culture platform. This work led to the creation of a QMUL spin-out company, where he served as Chief Scientific Officer. In this role, he led the development of advanced toxicology testing platforms for dermal absorption, irritation, and corrosion, and worked with industry partners to support new product development.
His research has generated four patents in dermatology-related technologies and over 20 peer-reviewed publications. He acts consultant to industry and regularly contributes to science communication pieces for the general public, bridging the gap between research, commercialisation, and public engagement.